Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-2248 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I: MK-2248 200 mg (Panel A) | EXPERIMENTAL | HCV participants will take MK-2248 200 mg by mouth once daily for 7 days. |
| Part I: MK-2248 ≤800 mg (Panel B) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part I: MK-2248 ≤800 mg (Panel C) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days. |
| Part I: MK-2248 ≤800 mg (Panel D) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part II: MK-2248 200 mg (Panel E) | EXPERIMENTAL | HCV participants will take MK-2248 200 mg by mouth once daily for 7 days. |
| Part II: MK-2248 ≤800 mg (Panel F) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part II: MK-2248 ≤800 mg (Panel G) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part II: MK-2248 ≤800 mg (Panel H) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part III: MK-2248 ≤800 mg (Panel I) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Part III: MK-2248 ≤800 mg (Panel J) | EXPERIMENTAL | Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days. |
| Name | Type | Description |
|---|---|---|
| MK-2248 | DRUG | MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days |
Inclusion Criteria: * clinical diagnosis of chronic HCV defined by positive serology for HCV or positive HCV RNA for at least 6 months and detectable HCV RNA in peripheral blood ≥10\^5 IU/mL at screening * Body Mass Index (BMI) ≥18 to \<37 kg/m\^2 * in good health other than HCV infection with norm...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
MK-2248 is an investigational small molecule being developed for the treatment of Hepatitis C. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and effectiveness.
MK-2248 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is in Phase 1 clinical development for Hepatitis C.
MK-2248 is in Phase 1 clinical development. It is an investigational drug for Hepatitis C and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed to evaluate its safety, pharmacokinetics, and pharmacodynamics.
MK-2248 has one completed clinical trial, NCT02161510, titled "Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)." This Phase 1 study enrolled 13 participants aged 18 years and older with Hepatitis C.
No alternative names for MK-2248 have been reported. The drug is identified by its code name MK-2248 and is being developed by Merck & Company, Inc. for the treatment of Hepatitis C.